INTRODUCTION

Nasopharyngeal carcinoma (NPC) is an endemic cancer in Southern China [1, 2]. NPC is a radiosensitive malignant tumor. Radiotherapy is the primary treatment modality for NPC. Xerostomia is a common radiation-induced late complication after radiotherapy [3]. The incidence of clinically significant xerostomia was more than 30% after intensity-modulated radiotherapy (IMRT) [4–6]. Xerostomia degrades the quality of life by disrupting eating, sleep, speech, and communication [7, 8]. Therefore, identifying predictive factors for xerostomia will lead to better treatments for patients with risks of severe xerostomia and improve the quality of life [9–11].

Currently, the potential predictive factors of xerostomia after IMRT in NPC patients remain unclear. Previous studies reported that the mean dose of the parotid glands was a predictor of xerostomia in patients with head and neck squamous cell carcinomas [12–17]; however, the most appropriate cut-off points for the mean dose differed significantly in previous studies [18–21]. Moreover, the xerostomia clinical factors require further assessment, including age, sex, pathology, tumour stage, chemotherapy, and volume of the parotid glands. Therefore, a distinct predictive model based on the dosimetric parameters and clinical variables would provide more accurate predictions than single parameters.
This study was conducted to identify the potential predictive dosimetric parameters of xerostomia and establish a predictive nomogram in NPC patients receiving IMRT.

RESULTS

Patient characteristics

This study included 195 patients: 102 patients in the grade 0-1 xerostomia group and 93 patients in the grade 2-3 xerostomia group. A flowchart is shown in Figure 1. The patient characteristics are shown in Table 1. The baseline clinical characteristics are balanced between the two group, except the N stage and the AJCC stage. All the patients received follow up for >12 months.

Predictors for xerostomia

The dosimetry parameters were comparable for the patients in the grade 0-1 xerostomia group and the grade 2-3 xerostomia group (Table 2). The predicted probability for the dosimetry parameters is listed in Table 2. The results indicate that each single parameter has a low assessment ability, which is less than 0.700.

Multivariate analysis of the logistic regression analysis revealed that V25, V30, V35, and V45 of the ipsilateral parotid gland and mean dose to the contralateral parotid gland were independent predictive factors for grade 2-3 xerostomia 1 year after treatment (Table 3). The predicted probability for these independent parameters is shown in Figure 2A. The cut-off points of V25, V30, V35, and V45 of the ipsilateral parotid gland and the contralateral parotid gland mean dose are 62.23%, 53.59%, 46.62%, 33.02%, and 39.63 Gy, respectively. The AUC of the combined predictor (mx) for grade 2-3 xerostomia 1 year after treatment is 0.756 (95% CI: 0.689-0.823, P <0.001) (Figure 2B).

Prognostic nomogram for xerostomia

The prognostic nomogram that integrated all the clinical variables and combined predictors is shown in Figure 3. The concordance index of the prognostic nomogram was 0.796 (95% CI: 0.735-0.857, P <0.001). The calibration plot for the probability of grade 2-3 xerostomia 1 year after treatment showed an optimal agreement between the predictive value from the nomogram and actual observation (Figure 4A). The predicted probability of the prognostic nomogram is 0.796 (95% CI: 0.734-0.857, P <0.001) (Figure 4B).

Figure 1. Flowchart depicting patient selection.
Table 1. Patient characteristics for grade 0-1 and grade 2-3 xerostomia 1 year post-treatment.

|                      | Grade 0-1 xerostomia (n=102) | Grade 2-3 xerostomia (n=93) | P     |
|----------------------|------------------------------|------------------------------|-------|
| Age at diagnosis (years) |                              |                              | 0.152 |
| Median               | 47                           | 47                           |       |
| Range                | 15-62                        | 24-74                        |       |
| Sex                  |                              |                              | 0.144 |
| Male                 | 80(78.4%)                    | 64(68.8%)                    |       |
| Female               | 22(21.6%)                    | 29(31.2%)                    |       |
| T stage              |                              |                              | 0.147 |
| T1                   | 9(8.8%)                      | 3(3.2%)                      |       |
| T2                   | 33(32.4%)                    | 29(31.2%)                    |       |
| T3                   | 26(25.5%)                    | 18(19.4%)                    |       |
| T4                   | 34(33.3%)                    | 43(46.2%)                    |       |
| N stage              |                              |                              | 0.010 |
| N0                   | 10(9.8%)                     | 1(1.1%)                      |       |
| N1                   | 47(46.1%)                    | 33(35.5%)                    |       |
| N2                   | 35(34.3%)                    | 44(47.3%)                    |       |
| N3                   | 10(9.8%)                     | 15(16.1%)                    |       |
| AJCC stage           |                              |                              | 0.007 |
| I                    | 4(3.9%)                      | 0(0.0%)                      |       |
| II                   | 27(26.5%)                    | 11(11.8%)                    |       |
| III                  | 31(30.4%)                    | 29(31.2%)                    |       |
| IVa-b                | 40(39.2%)                    | 53(57.0%)                    |       |
| Pathology            |                              |                              | 0.383 |
| WHO II               | 15(14.7%)                    | 9(9.7%)                      |       |
| WHO III              | 87(85.3%)                    | 84(90.3%)                    |       |
| BMI (kg/m²)          |                              |                              | 0.585 |
| <18.5                | 5(4.9%)                      | 5(5.4%)                      |       |
| 18.5-22.9            | 53(52.0%)                    | 41(44.1%)                    |       |
| 22.9-27.5            | 40(39.2%)                    | 40(43.0%)                    |       |
| ≥27.5                | 4(3.9%)                      | 7(7.5%)                      |       |
| Chemotherapy         |                              |                              | 0.248 |
| No                   | 13(12.7%)                    | 7(7.5%)                      |       |
| Yes                  | 89(87.3%)                    | 86(92.5%)                    |       |

WHO: World Health Organization. AJCC: the American Joint Committee on Cancer.
BMI: body mass index.

**DISCUSSION**

The dosimetry parameters of the parotid glands have been commonly used for the prediction of xerostomia. Current controversies on the different dosimetry parameters focus on which dosimetric parameter is an independent predictive factor of xerostomia and whether additional risk factors, other than the dosimetric parameters, are important. These factors are not specifically developed for NPC patients, but rather for patients with head and neck squamous cell carcinomas. The predictive accuracy of these factors might be affected by these questions.

This study found that the predictive ability of each single dosimetric parameter ranged from 0.502 to 0.689
Table 2. Predicted probability of the dosimetry parameters for grade 2-3 xerostomia 1 year post-treatment.

| Dosimetry parameters (median, range) | Grade 0-1 xerostomia | Grade 2-3 xerostomia | P  | AUC | 95% CI | P   |
|-------------------------------------|----------------------|----------------------|----|-----|--------|-----|
| Contralateral parotid gland          |                      |                      |    |     |        |     |
| CPG.Dmean (Gy)                      | 36.92 (29.75-48.57)  | 38.43 (29.32-74.10)  | 0.522 | 0.671 | 0.595-0.747 | <0.001 |
| CPG.V10 (%)                         | 100.00 (97.65-100.00) | 100.00 (99.72-100.00) | 0.473 | 0.571 | 0.504-0.638 | 0.020 |
| CPG.V15 (%)                         | 97.80 (84.38-100.00) | 99.15 (90.72-100.00) | 0.403 | 0.630 | 0.552-0.708 | 0.001 |
| CPG.V20 (%)                         | 84.86 (63.48-99.62)  | 88.81 (73.48-100.00) | 0.328 | 0.664 | 0.588-0.740 | <0.001 |
| CPG.V25 (%)                         | 67.04 (49.65-89.87)  | 69.93 (54.55-100.00) | 0.347 | 0.658 | 0.581-0.734 | <0.001 |
| CPG.V30 (%)                         | 54.96 (35.61-74.65)  | 58.16 (39.52-100.00) | 0.366 | 0.661 | 0.584-0.737 | <0.001 |
| CPG.V35 (%)                         | 46.94 (26.11-68.25)  | 49.54 (30.20-100.00) | 0.386 | 0.664 | 0.587-0.742 | <0.001 |
| CPG.V40 (%)                         | 40.51 (19.38-62.27)  | 42.24 (21.73-100.00) | 0.426 | 0.640 | 0.588-0.740 | <0.001 |
| CPG.V45 (%)                         | 34.20 (14.87-56.32)  | 36.50 (14.44-100.00) | 0.446 | 0.633 | 0.555-0.712 | 0.001 |
| CPG.Volume (cm³)                    | 30.02 (14.05-52.77)  | 25.97 (12.85-47.84)  | 0.378 | 0.612 | 0.532-0.692 | 0.003 |
| Ipsilateral parotid gland           |                      |                      |    |     |        |     |
| IPG.Dmean (Gy)                      | 35.51 (20.80-41.05)  | 36.56 (27.47-44.31)  | 0.382 | 0.646 | 0.569-0.723 | <0.001 |
| IPG.V10 (%)                         | 100.00 (95.77-100.00) | 100.00 (99.11-100.00) | 0.477 | 0.502 | 0.430-0.574 | 0.478 |
| IPG.V15 (%)                         | 97.10 (84.55-100.00) | 98.25 (90.06-100.00) | 0.482 | 0.604 | 0.524-0.683 | 0.006 |
| IPG.V20 (%)                         | 82.14 (50.72-95.72)  | 86.25 (71.63-99.15)  | 0.426 | 0.666 | 0.591-0.742 | <0.001 |
| IPG.V25 (%)                         | 63.60 (19.29-77.66)  | 67.99 (48.79-90.21)  | 0.406 | 0.689 | 0.616-0.763 | <0.001 |
| IPG.V30 (%)                         | 52.13 (6.91-67.05)   | 54.59 (32.02-76.90)  | 0.446 | 0.687 | 0.613-0.761 | <0.001 |
| IPG.V35 (%)                         | 43.94 (2.92-54.41)   | 46.71 (22.27-64.84)  | 0.446 | 0.675 | 0.598-0.751 | <0.001 |
| IPG.V40 (%)                         | 37.54 (1.40-47.62)   | 39.81 (15.21-54.48)  | 0.446 | 0.647 | 0.569-0.726 | <0.001 |
| IPG.V45 (%)                         | 31.11 (0.61-43.21)   | 33.09 (9.58-47.35)   | 0.426 | 0.607 | 0.527-0.686 | 0.005 |
| IPG.Volume (cm³)                    | 29.47 (14.63-58.54)  | 24.34 (15.02-47.39)  | 0.480 | 0.597 | 0.516-0.677 | 0.010 |

CPG: contralateral parotid gland. IPG: ipsilateral parotid gland. Dmean: mean dose. AUC: area under curve. CI: confidence interval.

Table 3. Logistic regression for grade 2-3 xerostomia 1 year post-treatment.

|             | Univariate | Multivariate |
|-------------|------------|--------------|
|             | OR        | 95% CI       | P   | OR        | 95% CI       | P   |
| CPG.Dmean   | 2.82      | 1.59-4.99    | <0.001 | 2.04      | 1.16-3.61    | 0.014 |
| IPG.V25     | 2.39      | 1.61-3.55    | <0.001 | 6.95      | 1.83-26.42   | 0.004 |
| IPG.V30     | 2.42      | 1.55-3.79    | <0.001 | 0.02      | 0.01-0.36    | 0.008 |
| IPG.V35     | 2.32      | 1.46-3.68    | <0.001 | 77.44     | 5.06-1184.51 | 0.002 |
| IPG.V45     | 1.45      | 1.05-2.00    | 0.023 | 0.19      | 0.0-0.56     | 0.003 |

CPG: contralateral parotid gland. IPG: ipsilateral parotid gland. Dmean: mean dose. OR: odds ratio. CI: confidence interval.
Figure 2. Predicted probability of the independent dosimetry parameters and combined predictors for grade 2-3 xerostomia at the 1 year follow-up. (A): Predicted probability of the independent dosimetry parameters. (B): Predicted probability of the combined predictors. CPG: contralateral parotid gland. IPG: ipsilateral parotid gland. Dmean: mean dose. AUC: area under the curve.

Figure 3. Nomogram of grade 2-3 xerostomia at the 1 year follow-up.
in AUC, which indicates low discrimination. Similarly, a prospective cohort analysis revealed the same results [22]; however, in the previous study, only V60 of the contralateral parotid gland (95% CI: 0.99-1.07, P = 0.080) was associated with near statistical significance with the presence of xerostomia. In contrast, the predictive probability of the combined predictors based on the results of multivariate analysis of the logistic regression analysis significantly increased to 0.756 in this study. Moreover, the predictive nomogram constructed based on the combined predictors and clinical variables performed well in predicting grade 2-3 xerostomia (AUC = 0.796), and the prediction was supported by the C-index and the calibration curve. Compared to the prospective study, the current retrospective study provides a better predictive model with high accuracy for xerostomia.

Several studies reported a correlation between the mean dose of the parotid glands and xerostomia in patients with head and neck squamous cell carcinomas 12–17. Our study also revealed a similar result: a mean dose ≥39.63 Gy to the contralateral parotid gland was a risk factor for grade 2-3 xerostomia; however, Sommat et al. [22] found that the mean dose to the parotid glands was not a predictive factor. Possible reasons for these opposing results may be that all patients in the study of Sommat et al. [22] had locoregionally advanced NPC and the dose distribution of the glands did not differ among the patients. In contrast, our cohort included early stage patients who received low dose treatment.

A mean dose <26 Gy for at least one parotid gland is recommended as a planning goal according to previous studies [20, 21]. Pre-treatment salivary flow rates can be completely recovered using this dose; however, this dose is hard to achieve in NPC patients. Because the tumour is close to the parotid glands, an overzealous effort in reducing doses to the parotid glands might decrease planning doses in the target volume, which is a risk for disease recurrence. Thus, the mean dose to the parotid glands in NPC patients was consistently more than 30 Gy. Our study indicated that the cut-off value of the mean dose to the contralateral parotid gland was 39.63 Gy. Similarly, Sommat et al. [22] reported that the average mean dose to the parotid glands was in excess of 41 Gy. Other studies revealed a dose range from 31.3 to 38 Gy [23–25].

In clinical practice, a V30 of <50% of the parotid gland is a commonly used criterion instead of the mean dose to the parotid glands. In this study, a V30 ≤53.59% to the ipsilateral parotid gland was a protective factor for xerostomia. Our results demonstrated that a V30 <50% to the parotid gland was a reasonable criterion; however, the addition of V25 <62.23% and V35 <46.62% criteria to the planning evaluation may further improve parotid function preservation. As indicated by the results of the multivariate logistic regression analysis, the predicted probability of V25 was the most accurate (AUC = 0.689).

Xerostomia was commonly observed 2 months after radiotherapy, and continuously improved thereafter [26]. Approximately 60% of patients recovered at least 25% of their baseline saliva secretion 1 year post treatment [27] and their salivary function became stable after 1 year. The incidence of xerostomia at the 1 year follow-up was similar to the 2 year [22]. Many patients may not recover salivary flow, and xerostomia remains consistent over time [28]. Therefore, xerostomia assessment 1 year after IMRT was reasonable in this study.

This study revealed that the incidence of grade 2-3 xerostomia at the 1 year follow-up was 47.69%, which indicates that xerostomia remained a significant long term

![Figure 4. Predicted probability of the nomogram. (A): The calibration plot of the nomogram for predicting grade 2-3 xerostomia at the 1 year follow-up. (B): Area under the curve of the nomogram.](image)
complication after IMRT; however, the incidence of xerostomia varied among previous studies. Our results are consistent with other reports. McDowell et al [6] reported that 46.7% of patients had grade 2-3 xerostomia after IMRT at the 4 year follow-up. Another study found that the incidence of grade 2-3 xerostomia was 43% [5]. In contrast, other studies reported that the incidence of grade 2-3 xerostomia ranged from 20.1% to 33% [4, 23, 29]. Possible reasons for these inconsistent findings could be differing patient inclusion criteria and follow-up time.

This study found that chemotherapy was not associated with grade 2-3 xerostomia, similarly to several other studies. Zeng et al [23] reported that chemotherapy had no impact on xerostomia in NPC patients treated with IMRT (P = 0.211). Moreover, Miah et al [5] assessed the incidence of xerostomia ≥ grade 2 between IMRT alone and concurrent chemoradiotherapy groups in 2 prospective studies. The authors found that the addition of chemotherapy to IMRT was not associated with the incidence of acute (60.3% vs 64.7%, P = 0.83) or late (34% vs 43%, P = 0.15) xerostomia. Our previous study also found no significant difference in dry mouth (P = 0.975) and sticky saliva (P = 0.358) between the radiotherapy and chemoradiotherapy groups based on patients’ self-reported xerostomia [30].

This study had several limitations. First, the nomogram was established based on data obtained from a single institution. The nomogram requires validation in another cohort. Second, this study did not assess the dosimetric parameters of the submandibular glands for xerostomia. Third, patients’ self-reported xerostomia may be a more reasonable assessment as it provides the patients’ perspective of xerostomia on quality of life, which might not be captured by physicians [31]. This study assessed xerostomia according to the RTOG/EORTC system. The subjective assessment of the RTOG/EORTC system may underestimate the severity of xerostomia compared with the patient self-reported scores [22, 32]. Therefore, the nomogram should be verified in a prospective cohort study with a patient self-reported and validated xerostomia questionnaire.

In conclusion, this study constructed a nomogram to accurately predict grade 2-3 xerostomia in NPC patients 1 year post-treatment with IMRT. Further studies are needed to verify whether the nomogram can be applied in clinical practice.

MATERIALS AND METHODS

Patients

This retrospective cohort study was conducted at Guangxi Medical University Cancer Hospital. NPC patients who were treated between September 2015 and March 2016 were assessed. The inclusion criteria included the following: (1) newly confirmed World Health Organization type II or III histology; (2) stage I-IIb NPC [7th edition of the American Joint Committee on Cancer (AJCC)]; and (3) patients received IMRT. Exclusion criteria were as follows: (1) palliative treatment; (2) previous malignancy; (3) pregnancy or lactation; (4) previous radiotherapy, chemotherapy, or surgery (except diagnostic) to the primary tumour or lymph nodes; (5) severe coexisting diseases included heart failure, uncontrolled diabetes, severe hepatitis, and renal dysfunction; and (6) diseases that affected the secretion of salivary glands.

This study was approved by Guangxi Medical University Cancer Hospital Ethics Committee. Informed consent was obtained from all the patients. This study did not register online due to the retrospective nature.

Treatment

IMRT was based on the International Commission on Radiation Units and Measurements Report 62 guidelines. The gross tumour volume of the nasopharynx (GTVnx) and gross tumour volume of the cervical lymph nodes (GTVnd) were quantified by using computed tomography (CT) or magnetic resonance imaging (MRI) scans. The high-risk clinical target volume (CTV1) included the GTVnx plus a 5–10 mm margin to encompass the high-risk sites of microscopic extension and the whole nasopharynx. The low-risk clinical target volume (CTV2) was defined as the CTV1 plus a 5–10 mm margin to encompass the low-risk sites of microscopic extension, including the skull base, the clivus, the sphenoid sinus, the parapharyngeal space, the pterygoid fossae, the posterior parts of the nasal cavity, the pterygopalatine fossae, the retropharyngeal nodal regions, and the elective neck area from level IB to V. The planning target volume (PTV) was defined by adding a 3 mm margin to the GTV or CTV. The prescribed radiation doses were 70.06-72.32 Gy for the PGTVnx, 66.00-72.32 Gy for the PGTVnd, 60.00-62.00 Gy for the PCTV1, and 54.00-55.80 Gy for the PCTV2.

Concurrent chemotherapy was 100 mg/m² of cisplatin for 1 or 3 days with 1 cycle on days 1, 22, and 43 during radiotherapy. Induction chemotherapy included 60 mg/m² of docetaxel for 1 day, 60 mg/m² of cisplatin for 1 day, and 600 mg/m²/day of 5-fluorouracil as a continuous intravenous infusion for 120 hours for 3 cycles.

Dosimetric parameters

All the parotid glands were contoured based on the fusion images from the MRI-CT-Sim to reduce observer
variability. No margin was added during treatment planning for the parotid glands. The dosimetric parameters were calculated from the dose-volume histograms in the radiotherapy planning system of Pinnacle³ 9.8 (Philips Co., Eindhoven, Netherlands). The pre-treatment parameters included the mean dose to the ipsilateral and the contralateral parotid glands, the volume of the ipsilateral and the contralateral parotid glands, and V10, V15, V20, V25, V30, V35, V40, V45, V50, V55 of the ipsilateral and the contralateral parotid glands.

Xerostomia assessment

Xerostomia was assessed by physicians at 3 months, 6 months, and 12 months after treatment according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) system [33]. Grade 1 complication was defined as slight dryness not affecting quality of life. Grade 2 complication was defined as moderate dryness that required a water bottle. Grade 3 complication was defined as severe dryness that caused a profound change in the quality of life. Xerostomia was assessed independently by 2 physicians (PXB and LY). Differences were resolved by discussion with a third physician (ZXD).

Endpoints

The endpoint was xerostomia 1 year after treatment completion. The patients were divided into grade 0-1 and grade 2-3 xerostomia groups.

Statistical analysis

Significant differences of clinical variables and dosimetric parameters between grade 0-1 and grade 2-3 xerostomia groups 1 year post-treatment were assessed. Continuous characteristics of age and dosimetric parameters were compared using Student’s t-test or Mann-Whitney U test for variables with an abnormal distribution. Categorical characteristics of sex, T stage, N stage, AJCC stage, pathology, body mass index, and chemotherapy were compared using the Chi-square test or Fisher’s exact test. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve was used to assess the predicted probability. The predictive factors for xerostomia were analysed using logistic regression analysis. Combined predictor (mx) was calculated using the results of the multivariate analysis of logistic regression analysis. Statistical analyses were performed using SPSS Statistics Version 23.0 software (IBM Co., Armonk, NY, USA).

A nomogram was constructed based on the predictors combined with the clinical variables using the rms package in R version 3.5.3 (http://www.r-project.org/). A final model selection was performed by a backward stepdown selection process with the Akaike information criterion [34]. The performance of the nomogram was measured by a calibration plot. All P values were two sided. A P value <0.05 was considered statistically significant.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to declare.

FUNDING

This study was supported by the grant of the Research and Development Project of Guangxi (No. AB18221007).

REFERENCES

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66:115–32. https://doi.org/10.3322/caac.21338 PMID:26808342

2. Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011; 30:114–19. https://doi.org/10.5732/cjc.010.10377 PMID:21272443

3. Zheng Y, Han F, Xiao W, Xiang Y, Lu L, Deng X, Cui N, Zhao C. Analysis of late toxicity in nasopharyngeal carcinoma patients treated with intensity modulated radiation therapy. Radiat Oncol. 2015; 10:17. https://doi.org/10.1186/s13014-014-0326-z PMID:25582731

4. Zhao LN, Zhou B, Shi M, Wang JH, Xiao F, Xu M, Luo SQ, Xue Y, Li JP, Tan LN. Clinical outcome for nasopharyngeal carcinoma with predominantly WHO II histology treated with intensity-modulated radiation therapy in non-endemic region of China. Oral Oncol. 2012; 48:864–69. https://doi.org/10.1016/j.oraloncology.2012.03.001 PMID:22445296

5. Miah AB, Gulliford SL, Bhide SA, Zaidi SH, Newbold KL, Harrington KJ, Nutting CM. The effect of concomitant chemotherapy on parotid gland function following head and neck IMRT. Radiother Oncol. 2013; 106:346–51. https://doi.org/10.1016/j.radonc.2013.03.006 PMID:23540553

6. McDowell LJ, Rock K, Xu W, Chan B, Waldron J, Lu L, Ezzat S, Pothier D, Bernstein LJ, So N, Huang SH, Giuliani M, Hope A, et al. Long-Term Late Toxicity,
Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018; 102:340–52. https://doi.org/10.1016/j.ijrobp.2018.05.060 PMID:30191868

7. Lin A, Kim HM, Terrell JE, Dawson LA, Ship JA, Eisbruch A. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys. 2003; 57:61–70. https://doi.org/10.1016/S0360-3016(03)00361-4 PMID:12909216

8. Wang X, Eisbruch A. IMRT for head and neck cancer: reducing xerostomia and dysphagia. J Radiat Res (Tokyo). 2016 (Suppl 1); 57:i69–75. https://doi.org/10.1093/jrr/rrw047 PMID:27538846

9. Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, Deng X, Huang S, Lin C, Lu T. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014; 110:398–403. https://doi.org/10.1016/j.radonc.2013.10.020 PMID:24231245

10. Setton J, Han J, Kannarunimit D, Wuu YR, Rosenberg SA, DeSelm C, Wolden SL, Tsai MF, Fang FM, Chen MF. Scintigraphic assessment of salivary function after intensity-modulated radiotherapy for head and neck cancer: correlations with parotid dose and quality of life. Oral Oncol. 2013; 49:42–48. https://doi.org/10.1016/j.oraloncology.2012.08.013 PMID:22995588

11. Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, Han J, Wu G. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 2012; 104:286–93. https://doi.org/10.1016/j.radonc.2012.08.013 PMID:22995588

12. Chen WC, Lai CH, Lee TF, Hung CH, Liu KC, Tsai MF, Wang WH, Chen H, Fang FM, Chen MF. Scintigraphic assessment of salivary function after intensity-modulated radiotherapy for head and neck cancer: correlations with parotid dose and quality of life. Oral Oncol. 2013; 49:42–48. https://doi.org/10.1016/j.oraloncology.2012.07.004 PMID:22854066

13. Maes A, Weltens C, Flam P, Lambin P, Bogaerts R, Liu X, Baetens J, Hermans R, Van den Bogaert W. Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol. 2002; 63:203–11. https://doi.org/10.1016/S0167-8140(02)00013-0 PMID:12063010

14. Blanco AI, Chao KS, El Naqa I, Franklin GE, Zakarian K, Vivic M, Deasy JO. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 62:1055–69. https://doi.org/10.1016/j.ijrobp.2004.12.076 PMID:15990009

15. Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys. 2010 (Suppl 1); 76:S58–63. https://doi.org/10.1016/j.ijrobp.2009.06.090 PMID:20171519

16. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001; 50:695–704. https://doi.org/10.1016/S0360-3016(01)01512-7 PMID:11395238

17. Li Y, Taylor JM, Ten Haken RK, Eisbruch A. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2007; 67:660–69. https://doi.org/10.1016/j.ijrobp.2006.09.021 PMID:17141973

18. Liu WS, Lee SP, Lee JK, Su MC, Chen GD, Lee HS, Lee H. Factors influencing the parotid function in nasopharyngeal carcinoma treated with parotid-sparing radiotherapy. Jpn J Clin Oncol. 2006; 36:626–31. https://doi.org/10.1093/jjco/hyl098 PMID:17008345

19. Chambers MS, Garden AS, Rosenthal D, Ahamad A, Schwartz DL, Blanco AI, Chao KS, Morrison WH, Ang KK, Weber RS. Intensity-modulated radiotherapy: is xerostomia still prevalent? Curr Oncol Rep. 2005; 7:131–36. https://doi.org/10.1007/s11912-005-0039-4 PMID:15717947

20. Hey J, Setz J, Gerlach R, Janich M, Hildebrandt G, Vordermark D, Gernhardt CR, Kuhnt T. Parotid gland-recovery after radiotherapy in the head and neck region—36 months follow-up of a prospective clinical study. Radiat Oncol. 2011; 6:125. https://doi.org/10.1186/1748-717X-6-125 PMID:21951317

21. Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 1999; 45:577–87. https://doi.org/10.1016/S0360-3016(99)00247-3
22. Sommat K, Hussain A, Ong WS, Yit NL, Khoo JB, Soong YL, Wee JT, Fong KW, Tan TW. Clinical and dosimetric predictors of physician and patient reported xerostomia following intensity modulated radiotherapy for nasopharyngeal cancer - A prospective cohort analysis. Radiother Oncol. 2019; 138:149–57. https://doi.org/10.1016/j.radonc.2019.05.023 PMID:31265972

23. Zeng L, Tian YM, Sun XM, Chen CY, Han F, Xiao WW, Deng XW, Lu TX. Late toxicities after intensity-modulated radiotherapy for nasopharyngeal carcinoma: patient and treatment-related risk factors. Br J Cancer. 2014; 110:49–54. https://doi.org/10.1038/bjc.2013.720 PMID:24253503

24. Yao JJ, Chen FP, Zhou GQ, Zhang WJ, Xu L, Wang XJ, Lin L, Ma J, Sun Y. A prospective study on radiation doses to organs at risk (OARs) during intensity-modulated radiotherapy for nasopharyngeal carcinoma patients. Oncotarget. 2016; 7:21742–52. https://doi.org/10.18632/oncotarget.7826 PMID:26942881

25. Cao CN, Luo JW, Gao L, Yi JL, Huang XD, Wang K, Zhang SP, Qu Y, Li SY, Cai WM, Xiao JP, Zhang Z, Xu GZ. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma. Oral Oncol. 2013; 49:175–81. https://doi.org/10.1016/j.oraloncology.2012.08.013 PMID:23021729

26. McMillan AS, Pow EH, Kwong DL, Wong MC, Sham JS, Leung LH, Leung WK. Preservation of quality of life after intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: results of a prospective longitudinal study. Head Neck. 2006; 28:712–22. https://doi.org/10.1002/hed.20378 PMID:16475203

27. Kwong DL, Pow EH, Sham JS, McMillan AS, Leung LH, Leung WK, Chua DT, Cheng AC, Wu PM, Au GK. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer. 2004; 101:1584–93. https://doi.org/10.1002/cncr.20552 PMID:15378492

28. Pan XB, Chen KH, Huang ST, Jiang YM, Ma JL, Liang ZG, Qu S, Li L, Chen L, Zhu XD. Comparison of the efficacy between intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in stage II nasopharyngeal carcinoma. Oncotarget. 2017; 8:78096–104. https://doi.org/10.18632/oncotarget.17481 PMID:29100451

29. Wang W, Feng M, Fan Z, Li J, Lang J. Clinical outcomes and prognostic factors of 695 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Biomed Res Int. 2014; 2014:814948. https://doi.org/10.1155/2014/814948 PMID:25162028

30. Pan XB, Huang ST, Chen KH, Jiang YM, Ma JL, Qu S, Li L, Chen L, Zhu XD. Concurrent chemoradiotherapy degrades the quality of life of patients with stage II nasopharyngeal carcinoma as compared to radiotherapy. Oncotarget. 2017; 8:14029–38. https://doi.org/10.18632/oncotarget.14932 PMID:28152511

31. Ringash J. Survivorship and Quality of Life in Head and Neck Cancer. J Clin Oncol. 2015; 33:3322–27. https://doi.org/10.1200/JCO.2015.61.4115 PMID:26351336

32. Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006; 66:445–53. https://doi.org/10.1016/j.ijrobp.2006.05.002 PMID:16839705

33. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31:1341–46. https://doi.org/10.1016/0360-3016(95)00060-C PMID:7713792

34. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15:361–87. https://doi.org/10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 PMID:8668867